早期NSCLC ctDNA微小残留病检测共识:ATORG德尔菲研究
亚洲胸部肿瘤研究组召集27名专家,采用德尔菲法制定早期切除NSCLC中ctDNA-MRD检测的共识声明,共形成23条立场声明,除1条外均达成强共识。共识强调需定义MRD检测最低分析性能阈值、标准化报告指标及分析前处理规范,并指出当前检测特异性高但灵敏度可变,不支持临床试验外常规用于辅助治疗降阶。
要点
- 需定义MRD检测最低分析性能阈值并标准化报告指标。
- 临床试验中应统一采血时间点和术语以确认预后价值。
- 当前MRD检测灵敏度可变,临床试验外不常规用于辅助降阶。
核心结论
- 共识为MRD检测负责任的融入临床研究和实践提供实用框架。
研究设计与样本
- 亚洲胸部肿瘤研究组召集27名多学科专家,采用结构化德尔菲法制定共识声明。
主要发现
- 共形成23条立场声明,除1条外均达成强共识。
- 共识强调需定义MRD检测最低分析性能阈值、改进报告指标标准化及明确分析前处理指南。
- 当前MRD检测显示高特异性和阳性预测值,但灵敏度可变,限制临床试验外常规用于辅助治疗降阶。
关键数值与推荐
- 共23条立场声明,除1条外均达成强共识。
临床怎么用
- 临床研究中应统一血样采集时间点和术语以确认MRD检测预后价值。
- 拓宽可及性、可持续资金、持续共识建设和协作性真实世界数据生成对临床实施至关重要。
- 未来临床试验必须考虑不同驱动基因相关的独特生物学和不断变化的标准治疗。
局限性
- 当前MRD检测灵敏度可变,限制临床试验外常规用于辅助治疗降阶。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Minimal residual disease (MRD) detection using liquid biopsy is an emerging tool for risk stratification and monitoring for recurrence in resected early stage NSCLC. There is increasing need for clear guidance on its optimal clinical implementation. METHODS: The Asian Thoracic Oncology Research Group (ATORG) convened a multidisciplinary panel of 27 experts to develop a consensus statement on the clinical application of circulating tumor DNA-based MRD testing in early stage resected NSCLC, using a structured Delphi methodology. Statements were organized into the following broad thematic domains: assay validity and standardization; harmonization in research and trials; clinical application; challenges in implementation; consensus recommendations; infrastructure for regional MRD adoption; and roadmap for pragmatic trials. RESULTS: A total of 23 position statements were developed, of which all except one achieved strong consensus. The consensus highlighted the need to define minimum analytical performance thresholds for MRD assays, improve standardization of reporting metrics, and clear guidelines for pre-analytical handling. Harmonization of blood sampling time points and terminology across clinical trials is also essential to confirm the prognostic value of MRD assays. Although current MRD assays demonstrate high specificity and positive predictive value, variable sensitivity precludes routine use for adjuvant therapy de-escalation outside clinical trials. Broader access, sustainable funding, ongoing consensus building, and collaborative real-world data generation are also critical to support clinical implementation and adoption. Future clinical trials must account for the distinct biology and changing standards of care associated with different driver genes. CONCLUSION: These consensus recommendations provide a pragmatic framework to guide the responsible integration of MRD testing into clinical research and practice.
引用
- Tan AC, Liao BC, Li M, et al. Consensus Statement on ctDNA Minimal Residual Disease Testing in Early Stage NSCLC: A Delphi Study by the Asian Thoracic Oncology Research Group. J Thorac Oncol. 2026. PMID: 41903701. doi:10.1016/j.jtho.2026.103696
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。